Use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor

Patent metadata

Field	Value
Publication number	US-9333194-B2
Application number	US-50482309-A
Country	US
Kind code	B2
Filing date	Jul 17, 2009
Priority date	Jun 21, 2002
Publication date	May 10, 2016
Grant date	May 10, 2016

Abstract

The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have long been used extensively as antibacterial agents for treating tuberculosis or Gram-positive bacterial infections. The active ingredients of the present invention have excellent angiogenesis-inhibiting activity. The angiogenesis inhibitor of the present invention is effective for inhibition of angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis, inflammatory diseases, and angiogenesis accompanying cardiovascular remodeling, etc., and can be used as therapeutic agents against each disease, etc. Further, the screening method of the present invention makes it possible to perform an effective screening of angiogenesis-inhibiting substances by detecting angiogenesis-inhibiting signals based on gene expression levels.

First claim

What is claimed is:

1. A method of inhibiting a tumor induced angiogenesis comprising administering to a malignant tumor patient an effective amount of rifampicin as an active ingredient.

2. The method according to claim 1 , wherein the rifampicin is a pharmacologically acceptable salt or a hydrate thereof.

3. The method according to claim 1 , wherein the rifampicin is administered orally to a malignant tumor patient.

4. The method according to claim 3 , wherein the effective amount is 50-1000 mg of the active ingredient.

5. The method according to claim 3 , wherein the effective amount is 150-500 mg of the active ingredient.

6. The method according to claim 1 , wherein the rifampicin is administered parenterally to a malignant tumor patient.

7. A method of treating a malignant tumor comprising administering to a malignant tumor patient an effective amount of rifampicin as an active ingredient, wherein the malignant tumor is treated by inhibiting a tumor induced angiogenesis.

8. The method according to claim 7 , wherein the rifampicin is a pharmacologically acceptable salt or a hydrate thereof.

9. The method according to claim 7 , wherein the rifampicin is administered orally to a malignant tumor patient.

10. The method according to claim 9 , wherein the effective amount is 50-1000 mg of the active ingredient.

11. The method according to claim 9 , wherein the effective amount is 150-500 mg of the active ingredient.

12. The method according to claim 7 , wherein the rifampicin is administered parenterally to a malignant tumor patient.

Assignees

• Shichiri Masayoshi
• Tanaka Yujiro
• Japan Science & Tech Agency

Inventors

• Shichiri Masayoshi
• Tanaka Yujiro

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• G01N33/5011

  for testing antineoplastic activity · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title